News

BMJ6d
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial - Annals of the Rheumatic ...
Background Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. Methods The GLORIA (Glucocorticoid LOw-dose in ...
BMJ6d
How to monitor SLE in routine clinical practice
A century ago syphilis was regarded as the great masquerader. Its modern equivalent is lupus. It may present to a wide range of specialists and its outcome, while much improved, remains uncertain in a ...
BMJ6d
Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7 - Annals of the Rheumatic Diseases
Objectives To investigate the role of mechanical stress in cartilage ageing and identify the mechanistic association during osteoarthritis (OA) progression. Methods F-box and WD repeat domain ...
BMJ6d
Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at ...
Objective To compare the relative bioavailability, safety and tolerability of oral methotrexate (MTX) and subcutaneous (SC) MTX administered via an auto-injector (MTXAI) in patients with rheumatoid ...
BMJ6d
Gout: why is this curable disease so seldom cured?
Gout is the most common inflammatory arthritis and one in which pathogenesis and risk factors are best understood. One of the treatment objectives in current guidelines is ‘cure’. However, audits show ...
BMJ6d
AB1245 AVACOPAN IN ANCA-ASSOCIATED VASCULITIS RECEIVED INTENSIFIED INDUCTION THERAPY WITH CYCLOPHOSPHAMIDE PLUS RITUXIMAB – RETROSPECTIVE OBSERVATION TWO-CENTRE STUDY …
Background: The novel therapeutic principle of complement C5 inhibition by avacopan was approved for the treatment of ANCA-associated vasculitis (AAV), in particular for granulomatosis with ...